{"id":"NCT00365300","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study of the Efficacy and Safety of Pantoprazole Sodium Enteric-Coated Granules in Infants (1 Through 11 Months) With Symptomatic GERD.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2006-08-17","resultsPosted":"2010-01-07","lastUpdate":"2010-05-04"},"enrollment":129,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux"],"interventions":[{"type":"DRUG","name":"pantoprazole","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pantoprazole","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).","primaryOutcome":{"measure":"Number of Patients Withdrawn From Study Due to Lack of Efficacy.","timeFrame":"4 weeks double-blind","effectByArm":[{"arm":"Pantoprazole Sodium Granules","deltaMin":6,"sd":null},{"arm":"Placebo","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"1.0"}]},"eligibility":{"minAge":"28 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":129},"commonTop":["Upper respiratory infection","Fever","Diarrhea","Otitis media","Rhinitis"]}}